Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study.
Sullivan SD, Nicholls CJ, Gupta RA, Menon AA, Wu J, Westerbacka J, Bosnyak Z, Frias JP, Bailey TS. Sullivan SD, et al. Among authors: westerbacka j. Diabetes Obes Metab. 2019 Sep;21(9):2123-2132. doi: 10.1111/dom.13793. Epub 2019 Jun 21. Diabetes Obes Metab. 2019. PMID: 31144445 Free PMC article.
Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.
Zhou FL, Ye F, Berhanu P, Gupta VE, Gupta RA, Sung J, Westerbacka J, Bailey TS, Blonde L. Zhou FL, et al. Among authors: westerbacka j. Diabetes Obes Metab. 2018 May;20(5):1293-1297. doi: 10.1111/dom.13199. Epub 2018 Jan 24. Diabetes Obes Metab. 2018. PMID: 29272064 Free PMC article.
Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
Sullivan SD, Bailey TS, Roussel R, Zhou FL, Bosnyak Z, Preblick R, Westerbacka J, Gupta RA, Blonde L. Sullivan SD, et al. Among authors: westerbacka j. Diabetes Obes Metab. 2018 Sep;20(9):2148-2158. doi: 10.1111/dom.13345. Epub 2018 Jun 25. Diabetes Obes Metab. 2018. PMID: 29938887 Free PMC article.
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study.
Cheng A, Harris S, Giorgino F, Seufert J, Ritzel R, Khunti K, Lauand F, Melas-Melt L, Westerbacka J, Bosnyak Z, Rosenstock J. Cheng A, et al. Among authors: westerbacka j. Diabetes Obes Metab. 2020 Mar;22(3):346-354. doi: 10.1111/dom.13901. Epub 2019 Dec 20. Diabetes Obes Metab. 2020. PMID: 31646724 Free PMC article. Clinical Trial.
Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N, Mauricio D, Giaccari A, Bailey T, Roussel R, Franco D, Berthou B, Pilorget V, Westerbacka J, Bosnyak Z, Bonnemaire M, Cali AMG, Nguyên-Pascal ML, Penfornis A, Perez-Maraver M, Seufert J, Sullivan SD, Wilding J, Wysham C, Davies M. Freemantle N, et al. Among authors: westerbacka j. Curr Med Res Opin. 2020 Apr;36(4):571-581. doi: 10.1080/03007995.2019.1708287. Epub 2020 Jan 19. Curr Med Res Opin. 2020. PMID: 31865758 Free article. Clinical Trial.
Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial.
Haluzík M, Cheng A, Müller-Wieland D, Westerbacka J, Bosnyak Z, Lauand F, Melas-Melt L, Karalliedde J, Rosenstock J, Bolli GB. Haluzík M, et al. Among authors: westerbacka j. Diabetes Obes Metab. 2020 Aug;22(8):1369-1377. doi: 10.1111/dom.14043. Epub 2020 Apr 28. Diabetes Obes Metab. 2020. PMID: 32243043 Free PMC article. Clinical Trial.
Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study.
Sullivan SD, Freemantle N, Gupta RA, Wu J, Nicholls CJ, Westerbacka J, Bailey TS. Sullivan SD, et al. Among authors: westerbacka j. Endocrinol Diabetes Metab. 2022 Jan;5(1):e00306. doi: 10.1002/edm2.306. Epub 2021 Nov 22. Endocrinol Diabetes Metab. 2022. PMID: 34807513 Free PMC article.
83 results